Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Wild-type TP53 defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs.

Zhang C, Martinez-Ledesma E, Gao F, Zhang W, Ding J, Wu S, Li X, Wu J, Yuan Y, Koul D, Alfred Yung WK.

Am J Cancer Res. 2019 Aug 1;9(8):1734-1745. eCollection 2019.

2.

Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.

Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado M.

Cancer. 2019 Feb 1;125(3):424-433. doi: 10.1002/cncr.31811. Epub 2018 Oct 25. Erratum in: Cancer. 2019 Apr 15;125(8):1387.

3.

APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death.

Wang Y, Wu S, Zheng S, Wang S, Wali A, Ezhilarasan R, Sulman EP, Koul D, Alfred Yung WK.

Oncotarget. 2017 Apr 21;8(33):54285-54296. doi: 10.18632/oncotarget.17348. eCollection 2017 Aug 15.

4.

Role of AKT signaling in DNA repair and clinical response to cancer therapy.

Liu Q, Turner KM, Alfred Yung WK, Chen K, Zhang W.

Neuro Oncol. 2014 Oct;16(10):1313-23. doi: 10.1093/neuonc/nou058. Epub 2014 May 7. Review.

5.

Neuro-oncology: past milestones and the journey ahead.

Alfred Yung WK.

Neuro Oncol. 2013 Nov;15(11):1453-4. doi: 10.1093/neuonc/not196. No abstract available.

6.

PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis.

Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Alfred Yung WK, Lu Z.

Cell. 2012 Aug 17;150(4):685-96. doi: 10.1016/j.cell.2012.07.018. Erratum in: Cell. 2014 Aug 28;158(5):1210.

7.

Current clinical development of PI3K pathway inhibitors in glioblastoma.

Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK.

Neuro Oncol. 2012 Jul;14(7):819-29. doi: 10.1093/neuonc/nos117. Epub 2012 May 22. Review.

8.

Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway.

Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, Guan S, Chen Z, Alfred Yung WK, Priebe W, Colman H.

J Neurooncol. 2012 May;107(3):487-501. doi: 10.1007/s11060-011-0786-z. Epub 2012 Jan 17.

PMID:
22249692
9.

Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial.

Reardon DA, Wen PY, Alfred Yung WK, Berk L, Narasimhan N, Turner CD, Clackson T, Rivera VM, Vogelbaum MA.

Cancer Chemother Pharmacol. 2012 Apr;69(4):849-60. doi: 10.1007/s00280-011-1773-y. Epub 2011 Oct 30.

PMID:
22037923
10.

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.

Reardon DA, Cloughesy T, Rich J, Alfred Yung WK, Yung L, DiLea C, Huang J, Dugan M, Mietlowski W, Maes A, Conrad C.

Cancer Chemother Pharmacol. 2012 Jan;69(1):281-7. doi: 10.1007/s00280-011-1754-1. Epub 2011 Oct 9.

PMID:
21984222
11.

Review of the complexities of the PI3K/mTOR pathway presages similar handling of other critical topics.

Alfred Yung WK.

Neuro Oncol. 2010 Aug;12(8):763-4. doi: 10.1093/neuonc/noq083. Review. No abstract available.

12.

Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.

Gwak HS, Shingu T, Chumbalkar V, Hwang YH, DeJournett R, Latha K, Koul D, Alfred Yung WK, Powis G, Farrell NP, Bögler O.

Int J Cancer. 2011 Feb 15;128(4):787-96. doi: 10.1002/ijc.25394.

13.

Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.

Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu VH, Hunter K, Meyers C, Hess KR, Alfred Yung WK.

Br J Cancer. 2009 Aug 18;101(4):615-20. doi: 10.1038/sj.bjc.6605189.

14.

Gamma-radiation sensitivity and risk of glioma.

Bondy ML, Wang LE, El-Zein R, de Andrade M, Selvan MS, Bruner JM, Levin VA, Alfred Yung WK, Adatto P, Wei Q.

J Natl Cancer Inst. 2001 Oct 17;93(20):1553-7.

PMID:
11604478
15.

Modulation of endothelial cell morphogenesis in vitro by MMP-9 during glial-endothelial cell interactions.

Chandrasekar N, Jasti S, Alfred-Yung WK, Ali-Osman F, Dinh DH, Olivero WC, Gujrati M, Kyritsis AP, Nicolson GL, Rao JS, Mohanam S.

Clin Exp Metastasis. 2000;18(4):337-42.

PMID:
11448065

Supplemental Content

Loading ...
Support Center